Iron Salts (Oral)

Clinical Comparison

Parameter Ferrous Sulfate Ferrous Fumarate Ferrous Gluconate Polysaccharide-Iron Complex (PIC) Carbonyl Iron
Iron oxidation state Fe²⁺ Fe²⁺ Fe²⁺ Fe³⁺ (complexed) Elemental Fe⁰
Elemental iron content ~20% ~33% ~12% ~100% (complexed) ~100%
Typical tablet strength 325 mg 300–325 mg 325 mg 100–150 mg elemental Fe 45–65 mg elemental Fe
Elemental iron per tablet ~65 mg ~100–108 mg ~35–38 mg As labeled As labeled
Usual adult dose (IDA) 60–120 mg elemental Fe/day 60–120 mg/day 60–120 mg/day 100–150 mg/day 100–200 mg/day
Absorption mechanism DMT-1 (duodenum) DMT-1 DMT-1 Requires reduction to Fe²⁺ Slow gastric dissolution
Relative bioavailability High (reference standard) High Moderate Variable Moderate
Food effect ↓ absorption ~40–50% ↓ absorption ↓ absorption Less food-dependent Less food-dependent
GI adverse effects High High Moderate Lower Lower
Common GI ADRs Nausea, epigastric pain, constipation, diarrhea Same as sulfate Same but milder Dyspepsia uncommon Constipation less common
Dose flexibility Moderate Less flexible (higher Fe load) High High Moderate
Drug–drug interactions Many (PPIs, antacids, Ca, levothyroxine, tetracyclines, fluoroquinolones) Same Same Fewer (still clinically relevant) Fewer
Risk in overdose High (esp. pediatrics) High High Lower Lower
Cost / availability Very low / widely available Low Low–moderate Higher Higher
Pregnancy use First-line Acceptable Acceptable Acceptable Acceptable
Use in CKD Effective but poorly tolerated Same Often preferred Common alternative Alternative
Adherence considerations Poor tolerance limits adherence Higher Fe → more GI effects Better tolerated, more pills Better tolerance, higher cost Better safety profile

Practical Clinical Pharmacist Insights

  • First-line choice
    • Ferrous sulfate remains first-line due to robust efficacy, low cost, and strong evidence base.
    • Switch if intolerance occurs rather than escalating dose.
  • Tolerability-driven selection
    • Ferrous gluconate or PIC preferred in patients with:
      • Prior GI intolerance
      • Pregnancy-related nausea
      • Inflammatory bowel disease (mild)
  • Elemental iron ≠ absorbed iron
    • Higher elemental iron (e.g., fumarate) does not guarantee better response and may worsen adherence.
  • Dosing strategy
    • Once-daily or alternate-day dosing improves absorption and tolerability by reducing hepcidin upregulation.
    • Target 40–65 mg elemental Fe per dose for most adults.
  • When to avoid oral iron
    • Poor response after 4–6 weeks (Hb ↑ <1 g/dL)
    • Active malabsorption, ongoing blood loss, severe intolerance → consider IV iron
  • Safety
    • Carbonyl iron and PIC have a lower risk of acute toxicity, useful in households with children.
 
1️⃣ Oral Iron Dosing Conversion Chart (Elemental Iron–Focused):

Therapeutic response plateaus above ~60–65 mg elemental iron per dose due to hepcidin-mediated absorption limits.

Iron Salt Common Product Strength Elemental Iron per Unit Doses to Approx. 60–65 mg Elemental Fe
Ferrous sulfate 325 mg tablet ~65 mg 1 tablet
Ferrous fumarate 300 mg tablet ~99 mg ~½–⅔ tablet*
Ferrous gluconate 325 mg tablet ~35 mg 2 tablets
Ferrous gluconate 300 mg tablet ~38 mg 2 tablets
Polysaccharide-iron complex Labeled as elemental Fe As labeled Product-dependent
Carbonyl iron 45 mg capsule 45 mg 1–2 capsules
*Splitting fumarate tablets may not always be feasible depending on formulation. Recommended adult strategy
  • 40–65 mg elemental iron once daily or every other day
  • Avoid routine TID dosing unless under specialist guidance

2️⃣ Formulary-Friendly Oral Iron Selection Algorithm Step 1: Confirm indication

  • Iron deficiency anemia (IDA) or iron deficiency without anemia
  • Rule out ongoing blood loss or malabsorption

⬇️ Step 2: First-line agent

  • Ferrous sulfate 325 mg once daily
    • Lowest cost
    • Strongest evidence base

⬇️ Step 3: Assess tolerance after 1–2 weeks

  • Mild GI effects → counsel on:
    • Taking with food (accept ↓ absorption)
    • Alternate-day dosing
  • Moderate–severe intolerance → switch salt

⬇️ Step 4: Intolerance-driven switch

  • Try ferrous gluconate (lower elemental Fe per tablet)
  • If still intolerant → polysaccharide-iron complex or carbonyl iron

⬇️ Step 5: Reassess response at 4–6 weeks

  • Expected: Hb ↑ ≥1 g/dL
  • If inadequate:
    • Check adherence, interactions, timing with food
    • Consider inflammatory state or malabsorption
    • Escalate to IV iron if appropriate

3️⃣ Oral Iron in Special Populations (Clinical Pharmacist View)

Population Preferred Oral Iron Rationale Key Counseling / Monitoring Points
Pregnancy Ferrous sulfate or gluconate Strong safety data Lower doses (30–60 mg/day); nausea common
Postpartum Ferrous sulfate Rapid repletion needed Consider IV if Hb <8 g/dL or poor tolerance
CKD (non-dialysis) Ferrous gluconate or PIC Better GI tolerability Monitor ferritin & TSAT; IV often needed
Dialysis CKD IV iron preferred Oral absorption poor Oral iron usually ineffective
IBD (quiescent) Ferrous gluconate or PIC Less mucosal irritation Avoid during active flare
IBD (active) IV iron Oral worsens inflammation Oral generally contraindicated
Bariatric surgery Carbonyl iron or PIC Better absorption distal to stomach Often require IV supplementation
Elderly Low-dose ferrous sulfate or gluconate Reduced GI tolerance Start low, titrate slowly
Pediatrics Ferrous sulfate liquid Best absorption Avoid carbonyl/iron salts with overdose risk
High overdose risk households Carbonyl iron or PIC Lower acute toxicity Still counsel on safe storage

High-Yield Pharmacist Counseling Points (Quick Reference)

  • Separate from interacting drugs by ≥2–4 hours (levothyroxine, fluoroquinolones, tetracyclines, calcium, PPIs)
  • Vitamin C not routinely required; benefit modest
  • Black stools are expected and benign
  • Constipation management improves adherence (fluids, fiber, stool softeners)
  • Treat 3 months beyond Hb normalization to replete stores
Tags: , , ,